-+ 0.00%
-+ 0.00%
-+ 0.00%

Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology

Benzinga·06/04/2026 12:39:39
Listen to the news

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, presented data today featuring its off-the-shelf CAR T-cell programs FT819 and FT839 at the European Congress of Rheumatology (EULAR) annual meeting being held in London, UK, June 3-6, 2026.